Growth hormone releasing activity by intranasal administration of a synthetic hexapeptide (hexarelin).

Laron Z, Frenkel J, Gil-Ad I, Klinger B, Lubin E, Wuthrich P, Boutignon F, Lengerts V, Deghenghi R

Clinical endocrinology1 Oct 1994Cited by 12 (Europe PMC)

PMID7955465DOI10.1111/j.1365-2265.1994.tb02589.xPepBankPUB-07955465

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

01HumanNon-randomized trialEfficacy outcome
Peak GH occurred at 15-30 minutes after intravenous hexarelin and between 30 and 60 minutes after intranasal hexarelin.
In plain wordsGrowth hormone peaked sooner after hexarelin into a vein than after hexarelin through the nose.
Peptide
Hexarelin
Outcome
Not applicableTime of peak GH after hexarelin
Study
n = 12
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg intravenous; 20 micrograms/kg intranasal · intravenous and intranasalAs given in this study (human).
Measurements
Time of peak GH
15 to 30 minutes
intravenous test
Time of peak GH
30 to 60 minutes
intranasal test
Source sentences
Summary
The peak GH in the i.v. test occurred at 15-30 minutes and in the i.n. test between 30 and 60 minutes.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546503
02HumanNon-randomized trialEfficacy outcome
There were no significant changes in plasma fT4 or T3 in any hexarelin test.
In plain wordsBlood fT4 and T3 did not change significantly in any hexarelin test.
Peptide
Hexarelin
Outcome
No significant changePlasma fT4 and T3 during hexarelin tests
Study
n = 12
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
1 microgram/kg intravenous; 20 micrograms/kg intranasal · intravenous and intranasalAs given in this study (human).
Source sentences
Summary
There were no significant changes in plasma fT4 or T3 in any of the tests.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546508
03HumanNon-randomized trialEfficacy outcome
The GH response to intranasal hexarelin was similar to that after intravenous hexarelin.
In plain wordsHexarelin through the nose gave a growth hormone response similar to hexarelin into a vein.
Peptide
Hexarelin
Outcome
No significant changeGH response to intranasal versus intravenous hexarelin
Study
n = 12
Comparator
Intravenous hexarelin
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 micrograms/kg · intranasalAs given in this study (human).
Source sentences
Summary
The GH response was similar to that observed after intravenous hexarelin.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546509
04HumanNon-randomized trialEfficacy outcome
In children with familial short stature, plasma TSH decreased during the intranasal hexarelin test.
In plain wordsIn short children, blood TSH fell during the hexarelin test given through the nose.
Peptide
Hexarelin
Outcome
DecreasePlasma TSH after intranasal hexarelin in children with familial short stature
Study
n = 10
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
20 micrograms/kg · intranasalAs given in this study (human).
Measurements
Plasma TSH after
0.64 mU/l
intranasal test
Source sentences
Summary
Plasma TSH decreased in the FSS children from a mean (+/- SD) of 1.0 +/- 0.26 to 0.64 +/- 0.2 mU/l (P < 0.005) during the i.n. test and from 1.0 +/- 0.3 to 0.7 +/- 0.3 mU/l (P < 0.05) during the i.v. test.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546505
05HumanNon-randomized trialEfficacy outcome
In children with familial short stature, plasma TSH decreased during the intravenous hexarelin test.
In plain wordsIn short children, blood TSH fell during the hexarelin test given into a vein.
Peptide
Hexarelin
Outcome
DecreasePlasma TSH after intravenous hexarelin in children with familial short stature
Study
n = 10
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Measurements
Plasma TSH after
0.7 mU/l
intravenous test
Source sentences
Summary
Plasma TSH decreased in the FSS children from a mean (+/- SD) of 1.0 +/- 0.26 to 0.64 +/- 0.2 mU/l (P < 0.005) during the i.n. test and from 1.0 +/- 0.3 to 0.7 +/- 0.3 mU/l (P < 0.05) during the i.v. test.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546506
06HumanNon-randomized trialEfficacy outcome
The GH-deficient patients showed no GH response to intravenous or intranasal hexarelin.
In plain wordsThe two GH-deficient patients had no growth hormone response to hexarelin by either route.
Peptide
Hexarelin
Outcome
No significant changeGH response in GH-deficient patients
Study
n = 2
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg intravenous; 20 micrograms/kg intranasal · intravenous and intranasalAs given in this study (human).
Source sentences
Summary
The GH deficient patients showed no GH response in either test.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546504
07HumanNon-randomized trialEfficacy outcome
In the isolated GH-deficient patient, plasma TSH decreased during both the intravenous and the intranasal hexarelin tests.
In plain wordsIn one GH-deficient patient, blood TSH fell during both hexarelin tests.
Peptide
Hexarelin
Outcome
DecreasePlasma TSH in an isolated GH-deficient patient
Study
n = 1
Outcome group
Thyroid function · Endocrine and hormones
Studied dose
1 microgram/kg intravenous; 20 micrograms/kg intranasal · intravenous and intranasalAs given in this study (human).
Source sentences
Summary
In the isolated GH deficient patient, plasma TSH decreased from 1.06 +/- 0.38 mU/l to 0.86 +/- 0.17 during the i.v. test and from 1.60 +/- 0.01 to 1.11 +/- 0.06 mU/l during the i.n. test.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546507
08HumanNon-randomized trialEfficacy outcome
In children with familial short stature and two GH-deficient patients, intranasal hexarelin induced a large GH response with a mean of 72.2 mU/l, but the GH-deficient patients had no GH response.
In plain wordsIn short children, hexarelin given through the nose caused a large rise in growth hormone, but two GH-deficient patients had no rise.
Peptide
Hexarelin
Outcome
IncreaseGH response to intranasal hexarelin
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
20 micrograms/kg · intranasalAs given in this study (human).
Measurements
Mean GH response
72.2 mU/l
intranasal test
Source sentences
Summary
Both the i.n. and i.v. administration of hexarelin induced a large GH response, the mean (+/- SD) being 72.2 +/- 35.5 mU/l for the i.n. test and 79.6 +/- 53.0 mU/l for the i.v. test.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546501
09HumanNon-randomized trialEfficacy outcome
In children with familial short stature and two GH-deficient patients, intravenous hexarelin induced a large GH response with a mean of 79.6 mU/l, but the GH-deficient patients had no GH response.
In plain wordsIn short children, hexarelin given into a vein caused a large rise in growth hormone, but two GH-deficient patients had no rise.
Peptide
Hexarelin
Outcome
IncreaseGH response to intravenous hexarelin
Study
n: not reported in source
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microgram/kg · intravenousAs given in this study (human).
Measurements
Mean GH response
79.6 mU/l
intravenous test
Source sentences
Summary
Both the i.n. and i.v. administration of hexarelin induced a large GH response, the mean (+/- SD) being 72.2 +/- 35.5 mU/l for the i.n. test and 79.6 +/- 53.0 mU/l for the i.v. test.
2 context sentences(design, population, supporting numbers)
Summary · context
Ten children with familial short stature (FSS) aged 5.5-15.5 years and two known GH deficient patients aged 24 and 28 years without GH treatment.
Summary · context
All 12 subjects were submitted to i.v. (1 microgram/kg) and i.n. (20 micrograms/kg) hexarelin tests with a one-week interval between tests.
Report a problemFND-0795546502

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.